BSBinayak Sinha

Binayak Sinha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Binayak Sinha has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis

    by Samit Ghosal, Binayak Sinha

    Background:The nonsteroidal mineralocorticoid antagonist finerenone is a new addition to the list of agents (angiotensin converting enzyme inhibitors and sodium glucose cotransporter 2 inhibitors) conferring renal protection to patients with diabetic kidney disease. Two recent meta-analyses using the fixed effect model in patients with chronic kidney disease (both diabetic and nondiabetic populations) came to a conflicting conclusion on the effect of finerenone on eGFR decline. This meta-analysis was undertaken exclusively in the type 2 diabetes (T2D) population to explore the robustness and heterogeneity of the effect size by conducting a random effects model meta-analysis along with draft plots and prediction intervals.Materials and methods:A database search was conducted using the Cochrane library to identify relevant citations. Analysis was conducted using RevMan 5.4.1 and R studio RStudio. (2022.07.1, Build 554). The hazard ratio was used as the effect size for the renal composite, while the standardized mean difference (SMD) was used to estimate the effect size of eGFR decline and reduction in the urine albumin creatinine ratio (UACR).Results:A pooled population of 13,943 patients from four citations was included for analysis. The Cochrane risk of bias was used to assess the quality of the studies. There was a significant 16% reduction in the renal composite (kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes) [HR: 0.84, 95% CI 0.77-0.92, t2: 0, I2: 0%). Finerenone was also associated with reduction in UACR (SMD: -0.49, 95% CI -0.53 to -0.46, t2: < 0.0001, I2: 0%, prediction interval: -0.57 to -0.41) and prevention of decline in eGFR (SMD: -0.32, 95% CI -0.37 to -0.27, t2: < 0.0001, I2: 0%, prediction interval: -0.43 to -0.21) without any evidence for significant heterogeneity. Except for an increase in hyperkalaemia (RR: 2.22, 95% CI 1.93-2.24), adverse events were observed with fineronone compared to placebo (RR: 1.00, 95% CI 0.98-1.01).Conclusion:There are significant benefits in renal outcomes associated with finerenone treatment in T2D patients with established chronic kidney disease with a side effect profile comparable to placebo.


  • Open Access

    Heterogeneity in cardiovascular deaths or hospitalizations for heart failure from cardiovascular outcome trials is linked to weight: A meta-regression analysis

    by Samit Ghosal, Binayak Sinha, Rik Mukherjee

    Background and aim Cardiovascular outcome trials with sodium–glucose cotransporter 2 inhibitors (SGLT-2is) have documented a positive impact on micro- and macrovascular complications of type 2 diabetes (T2D). Most analyses suggest that these benefits are independent of achieving metabolic control. This meta-regression analysis was undertaken to explore the relationship between metabolic components positively influenced by SGLT-2is and a reduction in cardiovascular death (CV death) or hospitalization due to heart failure (hHF). Materials and methods A database search was conducted using the Cochrane Library to identify relevant studies. Analysis was conducted using CMA and RStudio (2022.07.1) software. The hazard ratios of the individual studies were used to compute the random effects model mean effect size for CV death or hHF, and the prediction interval was used to identify the uncertainty in the summary treatment effect. Heterogeneity was quantified using Q statistics. Results A pooled population of 46,969 patients from five studies was included for analysis. The Cochrane risk of bias tool was used to assess the quality of the studies. There was a significant 23% reduction in CV deaths or hHFs in the SGLT-2i arm compared to the placebo arm (hazard ratio (HR): 0.77, 95% confidence interval (CI) 0.70–0.85). However, the prediction interval (0.57–1.05) and the Q statistic (8.06 > degrees of freedom (df) of 4) were indicative of uncertainty in the true effect or heterogeneity. Among the moderators selected, a significant correlation of the outcomes was found with the weight variable (p < 0.01). Conclusion The results of this meta-regression analysis suggest that the beneficial effects of SGLT-2is in reducing CV deaths and hHFs are related to the weight variable.

  • Open Access

    Using machine learning to assess cardiovascular risk in T2DM patients without established cardiovascular disease: The MARK-2 analysis

    by Samit Ghosal, Binayak Sinha

    Background:Cardiovascular (CV) risk assessment is the cornerstone for choosing the most appropriate antihyperglycemic agent. One of the major obstacles in the use of such scores is that the process is time consuming, which is a deterrent in a busy clinic. The aim of the present analysis was to explore means of reducing the number of inputs to make the scoring faster and more acceptable to physicians.Methods:We used the MARK survey dataset to assess the utility of the QRISK 3 CV risk score in the Indian population (n=1,538); participants were recruited from five zones (east, west, north, south, and central). Machine learning techniques were used to analyze the existing MARK data. The XGBoost algorithm was used to create the model needed to identify the clinical parameters of interest. Dimension reduction techniques were employed to identify the clinical parameters of importance based on the accrued gain values. As the final step, a confusion matrix was created to assess the model’s accuracy and precision.Results:We identified ten parameters of clinical interest that could predict the 10-year CV risk and were comparable with the QRISK 3 score (with 21 parameters). The parameters identified by machine learning (ML) were age, sex, BMI, smoking status, blood pressure, treatment with antihypertensive agents, angina, total cholesterol, the total cholesterol/HDL ratio, and CKD. This dimension reduction was possible with a model accuracy of 95.12%.Conclusion:There were ten routinely assessed parameters identified with machine learning techniques that can assist physicians in determining the CV risk of T2D patients within a short period of time.

  • Open Access

    The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis

    by Samit Ghosal, Binayak Sinha

    Backgrounds and Aims:Glucagon-like-peptides 1 receptor analogues (GLP1-RAs) have gained primacy in the management of type 2 diabetes (T2D) as their use is associated with significant metabolic benefits as well as positive macrovascular outcomes, as evidenced by several cardiovascular outcomes trials (CVOT). However, in contrast to the CVOT conducted with sodium glucose cotransporter-2 inhibitors (SGLT-2i) and dipeptidyl peptidase-4 Inhibitor (DPP-IVi), there was a significant reduction in glycated haemoglobin (HbA1c) in some of the CVOT with GLP1RA. The aim of this analysis is to explore the possible association between cardiovascular outcome benefits with GLP1-RAs and HbA1c reductionMethods:With the use of the Cochrane library a web search was conducted using keywords and 9 citations were selected for analysis. The analysis was performed using the comprehensive meta-analysis (CMA) software version 3 (Biostat Inc., Englewood, NJ, USA). A meta-regression analysis was performed using HbA1c, weight, and systolic blood pressure reduction as moderators explaining the variance in true effects across the citations. Result:The meta-regression analysis was conducted on a pooled population of 64,236 patients. There was a significant heterogeneity associated with the MACE benefits (Q=16.88, I2: 52.59, df=7, p=0.03). Among the moderators selected to explain the variance in true effects, HbA1c reduction was significant (Q=7.00, P=Conclusion: The MACE benefits associated with GLP1-RAs are dependent on the reduction of HbA1c levels.

  • The cardiovascular benefits of GLP1-RA are directly related to their positive effect on glycaemic control: A meta-regression analysis

    by Nightingale Hospital, Samit Ghosal, Binayak Sinha

    Review question / Objective: P (patient population) = Type 2 diabetes patients with high CV risk or established atherosclerotic cardiovascular disease; I (intervention) = Received drugs: GLP1-RA; C (control group) = Compared to a control group that received a placebo; O (outcome) = Outcomes of interest included primary CV outcomes (MACE, CV death, MI, and Stroke). Condition being studied: To explore whether the heterogeneity associated with the primary outcomes benefits can be attributed to the metabolic improvements associated with GLP1-RA. The plan is to use HBA1c, weight, and SBP reduction as moderators attempting to explain any variance between the true and observed effect size.

  • Open Access

    A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on metabolic parameters in patients with polycystic ovary syndrome (PCOS)

    by Binayak Sinha, Sami Ghosal

    Background Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among women of childbearing age and is associated with multiple morbidities. However, treatment for this condition is mainly applied for symptomatic relief and does not address the complex pathophysiology of this condition. This meta-analysis was conducted on the usage of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in PCOS because this group of drugs presents an attractive strategy to address the metabolic and hormonal defects by managing the pathophysiological defects observed in this syndrome. Methods We included prospective trials that enrolled patients with established PCOS and compared an SGLT-2i group versus a control group with at least 2 weeks of follow-up. The standardized mean difference (SMD) was used for effect size estimation from individual studies and was pooled using the fixed effect model. Results We included four trials with a pooled population of 158 patients with documented PCOS who received either an SGLT-2i or standard management. From a metabolic perspective, significant improvements were observed in the reduction in body weight (SMD: -0.68, 95% CI -1.16 to -0.19, < 0.01), fasting plasma glucose (FPG) (SMD: -0.59, 95% CI -0.99 to -0.19, P < 0.01), and insulin resistance as assessed with the HOMA-IR (SMD: -0.39, 95% CI -0.76 to -0.03, P = 0.03). In addition, a significant improvement was noted in dehydroepiandrosterone sulphate (DHEAS) levels (SMD: -0.55, 95% CI -0.94 to -0.16, P < 0.01). Conclusion SGLT-2i use is associated with salutary outcomes of metabolic and anthropometric markers of PCOS and likely favourable hormonal effects.

  • Open Access

    A target HbA1c between 7 – 7.7% reduces macrovascular events in T2D regardless of duration of diabetes – a meta-analysis of randomized controlled trials

    by Binayak Sinha, Samit Ghosal

    Introduction The target glycosylated haemoglobin (HbA1c) at which macrovascular benefits may be derived in type 2 diabetes (T2D) has never been clearly outlined. This meta-analysis was conducted on fifteen randomized controlled trials to highlight the association of HbA1c range with macrovascular events. Methods The association of different HbA1c clusters (intention to treat (ITT) and end-of-study [EOS]) range (less or equal than 6.5%, 6.6%–7.0%, 7.1%–7.7%) with macrovascular complications and also the combined effect of duration of T2D (< 10 years or ≥ 10 years) and HbA1c levels was assessed. Results Intensive glucose-lowering strategy resulted in a significant 13% reduction in non-fatal myocardial infarction (NFMI) (P=0.006). Based on HbA1c achieved, a significant 36% reduction in non-fatal stroke (P=0.008) and a 22% reduction in all-cause mortality (P=0.02) were observed in the group with HbA1c between 7.1% – 7.7% irrespective of diabetes duration. In the cohort, with diabetes duration Conclusion This is probably the first meta-analysis highlighting the importance of treating patients with T2D to a target HbA1C of 7 – 7.7%, as this target is associated with reduction in macrovascular events.

  • Open Access

    Meta‐analysis of the effects of sodium glucose cotransporter 2 inhibitors in non‐alcoholic fatty liver disease patients with type 2 diabetes

    by Binayak Sinha, Debasis Datta, Samit Ghosal

    Background and Aim: Sodium glucose cotransporter 2 inhibitors (SGLT‐2i), by way of their unique mode of action, present an attractive strategy for the treatment of type 2 diabetes and non‐alcoholic fatty liver disease (NAFLD), which often coexist and may lead to severe complications. However, the evidence for treatment with SGLT‐2i is limited to small heterogeneous studies. Therefore, this meta‐analysis was conducted to deduce the effects of SGLT‐2i in NAFLD with type 2 diabetes (T2D).Methods: A web‐based search identified nine randomized controlled trials from the Cochrane Library, Embase, and PubMed for this meta‐analysis. The Comprehensive Meta‐Analysis Software version 3 was used to calculate the effect size.Result: The outcomes of interest were analyzed from a pooled population of 11 369 patients—7281 on SGLT‐2i and 4088 in the control arm. SGLT‐2i therapy produced a statistically significant improvement in alanine aminotransferase [standardised mean difference (SDM), −0.21, 95% confidence interval (CI), −0.32 to −0.10, P < 0.01], aspartate aminotransferase (Standardised mean difference (SDM), −0.15, 95% CI, −0.24 to −0.07, P < 0.01), and liver fat as measured by proton density fat fraction (SDM, −0.98, 95% CI, −1.53 to −0.44, P < 0.01) in comparison to standard of care or placebo. In addition, there was a significant reduction in glycosylated hemoglobin (SDM, −0.37, 95% CI, −0.60 to −0.14, P < 0.01) and weight (SDM, −0.58, 95% CI, −0.93 to −0.23, P < 0.01) in the SGLT‐2i arm.Conclusion: This meta‐analysis provides a convincing signal that SGLT‐2i have a salutary effect on NAFLD in type 2 diabetes (T2D), probably driven by an improvement of glycemia and body weight, which in turn attenuates hepatic inflammation and hepatic fat accumulation.